Cabozantinib Versus Placebo In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy: Updated Results From The Phase Iii Cosmic-311 Trial And Prespecified Subgroup Analyses By Prior Therapy